
|Articles|July 1, 2004
Small interfering RNA targets VEGF for exudative AMD
Miami-Treatment with small interfering RNA (siRNA) directed against vascular endothelial growth factor (VEGF) is showing promise as a new therapy for choroidal neovascularization (CNV), according to Michael J. Tolentino, MD, who spoke at Angiogenesis 2004.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


